Decitabine cytotoxicity is promoted by dCMP deaminase DCTD and mitigated by SUMO-dependent E3 ligase TOPORS

被引:6
作者
Carnie, Christopher J. [1 ,2 ,3 ]
Gotz, Maximilian J. [4 ,5 ]
Palma-Chaundler, Chloe S. [1 ]
Weickert, Pedro [4 ,5 ]
Wanders, Amy [2 ,3 ]
Serrano-Benitez, Almudena [1 ,2 ,3 ]
Li, Hao-Yi [4 ,5 ]
Gupta, Vipul [2 ,3 ]
Awwad, Samah W. [1 ,2 ,3 ]
Blum, Christian J. [6 ]
Sczaniecka-Clift, Matylda [2 ,3 ]
Cordes, Jacqueline [4 ,5 ]
Zagnoli-Vieira, Guido [2 ,3 ]
D'Alessandro, Giuseppina [1 ,2 ,3 ]
Richards, Sean L. [1 ]
Gueorguieva, Nadia [1 ,2 ,3 ]
Lam, Simon [1 ,2 ,3 ]
Beli, Petra [6 ,7 ]
Stingele, Julian [4 ,5 ]
Jackson, Stephen P. [1 ,2 ,3 ]
机构
[1] Univ Cambridge, Canc Res UK Cambridge Inst, Cambridge, England
[2] Univ Cambridge, Gurdon Inst, Cambridge, England
[3] Univ Cambridge, Dept Biochem, Cambridge, England
[4] Ludwig Maximilians Univ Munchen, Gene Ctr, Munich, Germany
[5] Ludwig Maximilians Univ Munchen, Dept Biochem, Munich, Germany
[6] Inst Mol Biol IMB, Mainz, Germany
[7] Johannes Gutenberg Univ Mainz, Inst Dev Biol & Neurobiol IDN, Mainz, Germany
基金
欧洲研究理事会;
关键词
Genome Stability; DNA-Protein Crosslinks; Nucleotide Metabolism; SUMO-targeted Ubiquitylation; Hypomethylating Agents; PROTEIN CROSS-LINK; DNA-DEMETHYLATING AGENTS; ACUTE MYELOID-LEUKEMIA; MYELODYSPLASTIC SYNDROME; CANCER-CELLS; 5-AZA-2-DEOXYCYTIDINE; 5-AZA-2'-DEOXYCYTIDINE; METHYLTRANSFERASE; IDENTIFICATION; INHIBITORS;
D O I
10.1038/s44318-024-00108-2
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The nucleoside analogue decitabine (or 5-aza-dC) is used to treat several haematological cancers. Upon its triphosphorylation and incorporation into DNA, 5-aza-dC induces covalent DNA methyltransferase 1 DNA-protein crosslinks (DNMT1-DPCs), leading to DNA hypomethylation. However, 5-aza-dC's clinical outcomes vary, and relapse is common. Using genome-scale CRISPR/Cas9 screens, we map factors determining 5-aza-dC sensitivity. Unexpectedly, we find that loss of the dCMP deaminase DCTD causes 5-aza-dC resistance, suggesting that 5-aza-dUMP generation is cytotoxic. Combining results from a subsequent genetic screen in DCTD-deficient cells with the identification of the DNMT1-DPC-proximal proteome, we uncover the ubiquitin and SUMO1 E3 ligase, TOPORS, as a new DPC repair factor. TOPORS is recruited to SUMOylated DNMT1-DPCs and promotes their degradation. Our study suggests that 5-aza-dC-induced DPCs cause cytotoxicity when DPC repair is compromised, while cytotoxicity in wild-type cells arises from perturbed nucleotide metabolism, potentially laying the foundations for future identification of predictive biomarkers for decitabine treatment. The chemotherapeutic decitabine/5-aza-dC induces covalent DNMT1 DNA-protein crosslinks (DPCs), leading to DNMT1 degradation and DNA hypomethylation. This study finds that E3 ligase TOPORS promotes DNMT1-DPC degradation, while deaminase DCTD mediates a DNMT1-independent mode of 5-aza-dC cytotoxicity.The dCMP deaminase DCTD mediates 5-aza-dC cytotoxicity independently of DNA-protein crosslink formation, through the generation of 5-aza-dUMP. The ubiquitin and SUMO1 E3 ligase TOPORS is a novel player in global-genome DPC repair. TOPORS is recruited to SUMOylated DNMT1-DPCs through its SUMO-interaction motifs, whereupon it promotes DNMT1-DPC ubiquitylation and degradation. TOPORS acts in parallel to the E3 ubiquitin ligase RNF4 in mediating DNMT1-DPC tolerance. TOPORS acts in parallel to the ubiquitin ligase RNF4 in degradation of DNMT1-DNA crosslinks, thereby mediating cellular tolerance to these DPCs.
引用
收藏
页码:2397 / 2423
页数:27
相关论文
共 92 条
  • [1] CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil
    Almqvist, Helena
    Axelsson, Hanna
    Jafari, Rozbeh
    Dan, Chen
    Mateus, Andre
    Haraldsson, Martin
    Larsson, Andreas
    Molina, Daniel Martinez
    Artursson, Per
    Lundback, Thomas
    Nordlund, Par
    [J]. NATURE COMMUNICATIONS, 2016, 7
  • [2] The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
    Arber, Daniel A.
    Orazi, Attilio
    Hasserjian, Robert
    Thiele, Jurgen
    Borowitz, Michael J.
    Le Beau, Michelle M.
    Bloomfield, Clara D.
    Cazzola, Mario
    Vardiman, James W.
    [J]. BLOOD, 2016, 127 (20) : 2391 - 2405
  • [3] Recent developments in myelodysplastic syndromes
    Bejar, Rafael
    Steensma, David P.
    [J]. BLOOD, 2014, 124 (18) : 2793 - 2803
  • [4] How Much? How Frequent? How Long? A Clinical Guide to New Therapies in Myelodysplastic Syndromes
    Blum, William
    [J]. HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, : 314 - 321
  • [5] SUMOylation promotes protective responses to DNA-protein crosslinks
    Borgermann, Nikoline
    Ackermann, Leena
    Schwertman, Petra
    Hendriks, Ivo A.
    Thijssen, Karen
    Liu, Julio C. Y.
    Lans, Hannes
    Nielsen, Michael L.
    Mailand, Niels
    [J]. EMBO JOURNAL, 2019, 38 (08)
  • [6] Easy quantitative assessment of genome editing by sequence trace decomposition
    Brinkman, Eva K.
    Chen, Tao
    Amendola, Mario
    van Steensel, Bas
    [J]. NUCLEIC ACIDS RESEARCH, 2014, 42 (22)
  • [7] The ubipuitin ligase dTopors directs the nuclear organization of a chromatin insulator
    Capelson, M
    Corces, VG
    [J]. MOLECULAR CELL, 2005, 20 (01) : 105 - 116
  • [8] Transcription-coupled repair of DNA-protein cross-links depends on CSA and CSB
    Carnie, Christopher J.
    Acampora, Aleida C.
    Bader, Aldo S.
    Erdenebat, Chimeg
    Zhao, Shubo
    Bitensky, Elnatan
    van den Heuvel, Diana
    Parnas, Avital
    Gupta, Vipul
    DAlessandro, Giuseppina
    Sczaniecka-Clift, Matylda
    Weickert, Pedro
    Aygenli, Fatih
    Goetz, Maximilian J.
    Cordes, Jacqueline
    Esain-Garcia, Isabel
    Melidis, Larry
    Wondergem, Annelotte P.
    Lam, Simon
    Robles, Maria S.
    Balasubramanian, Shankar
    Adar, Sheera
    Luijsterburg, Martijn S.
    Jackson, Stephen P.
    Stingele, Julian
    [J]. NATURE CELL BIOLOGY, 2024, 26 (05) : 797 - 810
  • [9] Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS)
    Cashen, Amanda F.
    Shah, Ajit K.
    Todt, Laura
    Fisher, Nicholas
    DiPersio, John
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 61 (05) : 759 - 766
  • [10] CHABOT GG, 1983, CANCER RES, V43, P592